|
Market Closed -
NSE India S.E.
15:05:07 21/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 601.85 INR | +0.01% |
|
+1.33% | -14.63% |
| 07-31 | Astec LifeSciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
| 04-27 | Astec LifeSciences March-quarter consol net loss 77.6 million rupees | RE |
Company Valuation: Astec LifeSciences Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 34,391 | 27,154 | 20,932 | 13,243 | 12,046 | 13,411 | - | - |
| Change | - | -21.04% | -22.91% | -36.73% | -9.04% | 11.33% | - | - |
| Enterprise Value (EV) | 37,163 | 27,154 | 20,932 | 13,243 | 12,046 | 13,411 | 13,411 | 13,411 |
| Change | - | -26.93% | -22.91% | -36.73% | -9.04% | 11.33% | 0% | 0% |
| P/E | 38.3x | 106x | -44.6x | -9.83x | -14.3x | -48.1x | 54.7x | 20.8x |
| PBR | 8.68x | 6.47x | 5.67x | 5.64x | - | 3.71x | 3.26x | 2.83x |
| PEG | - | -1.5x | 0x | -0x | 0.3x | 0.7x | -0x | 0x |
| Capitalization / Revenue | 5.08x | 4.32x | 4.57x | 3.47x | - | 2.4x | 1.81x | 1.48x |
| EV / Revenue | 0x | 0x | 0x | 0x | - | 2.4x | 1.81x | 1.48x |
| EV / EBITDA | 0x | 0x | -0x | -0x | - | 29.9x | 12.8x | 8.91x |
| EV / EBIT | 0x | 0x | -0x | -0x | - | 25.3x | 17.5x | 10.5x |
| EV / FCF | -0x | - | - | - | - | -75.8x | -85.4x | 53.4x |
| FCF Yield | -2.34% | - | - | - | - | -1.32% | -1.17% | 1.87% |
| Dividend per Share 2 | 1.5 | 1.5 | - | - | - | 1.5 | 1.25 | 1.25 |
| Rate of return | 0.09% | 0.11% | - | - | - | 0.25% | 0.21% | 0.21% |
| EPS 2 | 45.85 | 13.04 | -23.93 | -68.71 | -37.79 | -12.5 | 11 | 28.9 |
| Distribution rate | 3.27% | 11.5% | - | - | - | -12% | 11.4% | 4.33% |
| Net sales 1 | 6,766 | 6,282 | 4,582 | 3,813 | - | 5,595 | 7,409 | 9,082 |
| EBITDA 1 | 1,541 | 762.5 | -59.13 | -662.1 | - | 448 | 1,044 | 1,504 |
| EBIT 1 | 1,197 | 426 | -421.7 | -1,099 | - | 530 | 767 | 1,276 |
| Net income 1 | 898.6 | 255.6 | -469.3 | -1,348 | -809.2 | -279 | 246 | 644.5 |
| Net Debt | 2,772 | - | - | - | - | - | - | - |
| Reference price 2 | 1,755.25 | 1,385.00 | 1,067.45 | 675.25 | 540.60 | 601.85 | 601.85 | 601.85 |
| Nbr of stocks (in thousands) | 19,593 | 19,606 | 19,609 | 19,611 | 22,282 | 22,283 | - | - |
| Announcement Date | 02/05/22 | 02/05/23 | 02/05/24 | 23/04/25 | 27/04/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -48.15x | - | - | 0.25% | 140M | |
| 31.82x | 2.96x | 12.75x | 0.91% | 54.57B | |
| 10.31x | 1.17x | 5.86x | 5.3% | 8.05B | |
| 15.27x | 1.13x | 5.92x | 1.56% | 5.03B | |
| 32.51x | 4.76x | 20.23x | 0.58% | 3.96B | |
| Average | 8.35x | 2.50x | 11.19x | 1.72% | 14.35B | |
| Weighted average by Cap. | 28.13x | 2.73x | 11.91x | 1.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ASTEC Stock
- Valuation Astec LifeSciences Limited
Select your edition
All financial news and data tailored to specific country editions
